Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol Myers Squibb to Acquire Mirati Therapeutics in Deal Worth Up to $5.8 Billion
06:12pm, Sunday, 08'th Oct 2023
The deal expands the pharmaceutical company's portfolio of cancer drugs.
Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal
05:56pm, Sunday, 08'th Oct 2023
Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing $4.8 billion equity value.
5 Low Beta, High-Yield Stocks for Your Low-Risk Income Portfolio
07:16am, Thursday, 05'th Oct 2023
The risk to the market is mounting, and with it, volatility. The VIX is up nearly 50% in the last month and heading higher, which means the S&P 500 could be heading lower.
Drugmakers agree to participate in Medicare price negotiations
12:31pm, Tuesday, 03'rd Oct 2023
Major drugmakers including Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ) and Merck & Co Inc (NYSE:MRK) have agreed to participate in the Inflation Reduction Act's (IRA's) Medicare Drug Pri
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
07:09pm, Monday, 02'nd Oct 2023
Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types of cancer treatments. CAR T involves “reprogramming” patients' T cells, which fight hostile c
Drugmakers opt in to Medicare drug price negotiations – here's what happens next
03:34pm, Monday, 02'nd Oct 2023
The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.
Drugmakers sign on to negotiate Medicare prices under protest
01:02pm, Monday, 02'nd Oct 2023
All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to part
Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024
11:32am, Monday, 02'nd Oct 2023
With a few exceptions, pharmaceutical stocks have underperformed the broader market this year. The S&P Pharmaceutical Index is down 3% year to date versus a 12% gain in the benchmark S&P 500.
3 Dividend Stocks to Buy and Hold Until Retirement
08:45am, Thursday, 28'th Sep 2023
Bristol Myers, Apple, and Verizon have been increasing their dividends in recent years. All three companies have sustainable payouts that should also rise in the future.
Bristol Myers Squibb: Close To Fair Value, Headwinds For Next Few Years
03:33am, Tuesday, 26'th Sep 2023
Since Bristol Myers Squibb acquired Celgene for $74 billion in 2019, the stock price has faced challenges and stagnation. The company's defensive strategy to defend the value of its legacy products ma
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
10:33pm, Sunday, 24'th Sep 2023
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big phar
Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.
04:00pm, Sunday, 24'th Sep 2023
Healthcare stocks generally offer a lot of upside. The cost of healthcare is incredibly expensive in the United States and the companies that deliver it tend to do very well overall.
Top Wall Street analysts are bullish on these dividend stocks
08:32am, Sunday, 24'th Sep 2023
TipRanks' analyst ranking service pinpoints Wall Street's best-performing stocks, including Chevron and Broadcom.
Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study
01:31pm, Friday, 22'nd Sep 2023
Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.
Bearish Bet on Pharma Stock Doubled Investors' Money
02:32pm, Monday, 18'th Sep 2023
Subscribers to Schaeffer's Leverage Trader service more than doubled their investment with our Bristol-Myers Squibb Co (NYSE:BMY) September 63 put recommendation, all in in just two weeks.
